RT Journal Article
SR Electronic
T1 Phenotyping Refractory Cardiogenic Shock Patients Receiving Venous-arterial Extracorporeal Membrane Oxygenation with Machine Learning Algorithms
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.04.20.23288900
DO 10.1101/2023.04.20.23288900
A1 Wang, Shuo
A1 Wang, Liangshan
A1 Du, Zhongtao
A1 Yang, Feng
A1 Hao, Xing
A1 Wang, Xiaomeng
A1 Shao, Chengcheng
A1 Li, Chenglong
A1 Wang, Hong
A1 Hou, Xiaotong
YR 2023
UL http://medrxiv.org/content/early/2023/04/26/2023.04.20.23288900.abstract
AB Background Refractory cardiogenic shock (CS) patients receiving venous-arterial extracorporeal membrane oxygenation (VA-ECMO) have a wide range of mortality, machine algorithm methods may explain the potential heterogeneity of these patients.Methods Between January 2018 and May 2021, 210 patients with CS who were receiving VA-ECMO support were enrolled and analyzed retrospectively. The k-means consensus agnostic algorithm was used. Patients were divided into three clusters based on covariates, such as platelet count (PLT), aspartic acid transaminase (AST), Interleukin-6 (IL-6), prothrombin time (PT), and serum lactate level 24 hours after ECMO initiation. The clinical and laboratory profiles were analyzed.Results Among 210 CS with CS receiving ECMO, 148 (70.5%) were men, with a median age of 62 years (interquartile range (IQR): 53-67). Overall, 104 (49.5%) patients survived to discharge with 142 (67.6%) survived on ECMO. The patients were phenotyped into three clusters: (1) “platelet preserved (I)” Phenotype (36 [17.1%] patients), characterized by a preserved platelet count; (2) “hyperinflammatory (II)” phenotype (72 [34.3%] patients), characterized by a significant inflammatory response with higher Interleukin-6 (IL-6), and Interleukin-10 (IL-10) levels; and (3) “hepatic-renal (III)” phenotype (102 [48.6%] patients), characterized by unfavorable conditions in creatinine, aspartic acid transaminase, alanine aminotransferase, direct bilirubin, and prothrombin time. The in-hospital mortality rates were 25.0%, 52.8%, and 55.9% for phenotypes I, II, and III, respectively (P = 0.005).Conclusion The consensus k-means algorithm analysis identified three phenotypes in refractory patients with CS receiving VA-ECMO: “platelet preserved,” “hyperinflammatory,” and “hepatic-renal.” The phenotypes are associated with the clinical profile and mortality, allowing treatment strategies for subsets of patients with CS receiving ECMO to be developed.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNational Natural Science Foundation of China (No. 82170400 to Xiaotong Hou): The mechanism of erythroid precursors regulate negatively monocytes immune function through Galectin-9-TIM3 pathway. National Natural Science Foundation of China (No. 81870305 to Xiaotong Hou): The negative regulation mechanism of co-inhibitory molecule TIGIT on the function of inflammatory monocytes in patients supported with ECMO. Beijing Hospitals Authority Clinical Medicine Development of Special Funding Support, Code: ZYLX202111. Beijing Hospitals Authority "Ascent Plan", Code: FDL20190601. Beijing Key Specialist Project for Major Epidemic Prevention and Control Supported by the National Key Research and Development Program of China (No. 2021YFC2701703) Beijing Nova Program (No. 2022064) Social Development Science and Technology Project (CYSF2215) from Chaoyang District Bureau of Science and Technology and Information TechnologyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the institutional ethics committee/review board of the Beijing Anzhen Hospital. Informed consent for demographic, physiological and hospital-outcome data analyses was not obtained because this observational study did not modify existing diagnostic or therapeutic strategies. However, patients and/or relatives were informed about the anonymous data collection and that they could decline inclusion.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Not ApplicableAll data referred to in the manuscript is objective and true,and will be available to reviewers if necessary.VA-ECMOVenoarterial extracorporeal membrane oxygenationCScardiogenic shockPLTplatelet countASTaspartic acid transaminaseIL-6Interleukin-6PTprothrombin timeMLMachine learningSAVEThe survival after VA-ECMO scoreAMIacute myocardial infarctionREMEMBERpRedicting mortality in patients undergoing veno-arterial Extracorporeal MEMBrane oxygenation after coronary artEry bypass gRaftingENCOURAGEprEdictioN of Cardiogenic shock OUtcome foR Acute myocardial infarction patients salvaGed by VA-ECMO scoreARDSacute respiratory distress syndromeLVEFleft ventricular ejection fractionLVEDDleft ventricular end-diastolic diameterNYHANew York Heart Association Functional ClassificationVISthe vasoactive inotropic scoreABGarterial blood gasMAPmean arterial pressureTSNE plott-distributed stochastic neighbor embedding plotIQRInterquartile rangeCRRTContinuous renal replacement therapySOFAThe Sepsis-related Organ Failure Assessment scoreROSreactive oxygen speciesox-LDLoxidized low-density lipoproteinMDAmalondialdehydeMODSmultiple organ disorder syndromeIABPintra-aortic balloon pumpCPBcardiopulmonary bypassCABGCoronary artery bypass graftingICUIntensive care unit